The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - Cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland

Swiss Medical Weekly

Volumn 144, Issue , 2014, Pages

  Ribi, Camillo ^a,g   Trendelenburg, Marten ^b   Gayet Ageron, Angèle ^a   Cohen, Clemens D ^c   Dayer, Eric ^d   Eisenberger, Ute ^e   Hauser, Thomas ^f   Hunziker, Thomas ^e   Leimgruber, Annette ^g   Lindner, Gregor ^e   Koenig, Katrin ^b   Otto, Petra ^h   Spertini, François ^g   Stoll, Thomas ⁱ   Von Kempis, Johannes ^h   Chizzolini, Carlo ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Hopital de Sion   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f Gruppenpraxis Immunologie Zentrum   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁱ Kantonsspital Schaffhausen   (Switzerland)

Author keywords

Cohort; Disease activity; Hydroxychloroquine; Lupus; Switzerland

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CHLOROQUINE; CLOPIDOGREL; CORTICOSTEROID; COUMARIN DERIVATIVE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; PREDNISONE; RITUXIMAB; ANTIMALARIAL AGENT;

ADULT; AFRICAN; ARTICLE; ASIAN; CAUCASIAN; CLINICAL ASSESSMENT TOOL; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; EUROPEAN; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NEPHROLOGIST; PRESCRIPTION; PROPENSITY SCORE; PROSPECTIVE STUDY; SAFETY OF ESTROGENS IN LUPUS ERYTHEMATOSUS NATIONAL ASSESSMENT SLE DISEASE ACTIVITY INDEX; SLEDAI; SWITZERLAND; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; AGED; BLOOD; CHILD; CLINICAL PRACTICE; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; IMMUNOLOGY; INTERNAL MEDICINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; NEPHROLOGY; ONSET AGE; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALLERGY AND IMMUNOLOGY; ANTIMALARIALS; BLOOD SEDIMENTATION; CHILD; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNAL MEDICINE; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NEPHROLOGY; PHYSICIAN'S PRACTICE PATTERNS; PROPENSITY SCORE; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; SWITZERLAND; YOUNG ADULT;

EID: 84907324793     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2014.13990     Document Type: Article

References (36)

1. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369(9561):587-96. (Pubitemid 46241445)
2. Chizzolini C, Cohen CD, Eisenberger U, Hauser T, Hunziker T, Leimgruber A, et al. Towards the Swiss systemic lupus erythematosus cohort study (SSCS). Rev Med Suisse. 2009;5(199):808-11.
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
4. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-7. (Pubitemid 13221242)
5. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550-8. (Pubitemid 41785892)
6. Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 2011;20(1):67-70.
7. Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford).50(5):982-8.
8. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-81.
9. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72(2):113-24. (Pubitemid 23097765)
10. Lalani S, Pope J, de Leon F, Peschken C, Members of Ca NFoL. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol. 2010;37(1):38-44.
11. Alonso MD, Martinez-Vazquez F, de Teran TD, Miranda-Filloy JA, Dierssen T, Blanco R, et al. Late-onset systemic lupus erythematosus in Northwestern Spain: differences with early-onset systemic lupus erythematosus and literature review. Lupus. 2012;21(10):1135-48.
12. Seligman VA, Lum RF, Olson JL, Li H, Criswell LA. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med. 2002;112(9):726-9. (Pubitemid 34655662)
13. Cervera R, Abarca-Costalago M, Abramovicz D, Allegri F, Annunziata P, Aydintug AO, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". Autoimmun Rev. 2006;5(3):180-6. (Pubitemid 43234182)
14. Costedoat-Chalumeau N, Leroux G, Piette JC, Amoura Z. Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment? Joint Bone Spine. 2010;77(1):4-5.
15. Lerang K, Gilboe IM, Gran JT. Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus. Rheumatology (Oxford). 51(4):663-9.
16. Schmajuk G, Yazdany J, Trupin L, Yelin E. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 62(3):386-92.
17. Molina MJ, Mayor AM, Franco AE, Morell CA, Lopez MA, Vila LM. Utilization of health services and prescription patterns among lupus patients followed by primary care physicians and rheumatologists in Puerto Rico. Ethn Dis. 2008;18(2 Suppl 2):S2-205-10.
18. Yazdany J, Gillis JZ, Trupin L, Katz P, Panopalis P, Criswell LA, et al. Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus. Arthritis Rheum. 2007;57(4):593-600. (Pubitemid 46764048)
19. Scherbel AL. Use of synthetic antimalarial drugs and other agents for rheumatoid arthritis: historic and therapeutic perspectives. Am J Med. 1983;75(1A):1-4. (Pubitemid 13025973)
20. Wallace DJ. The history of antimalarials. Lupus. 1996;5(Suppl 1):S2-3. (Pubitemid 26196733)
21. D'Cruz D. Antimalarial therapy: a panacea for mild lupus? Lupus. 2001;10(3):148-51. (Pubitemid 32410068)
22. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 7(12):718-29.
23. Vila LM, Alarcon GS, McGwin G, Jr., Bastian HM, Fessler BJ, Reveille JD. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol. 2005;32(11):2150-5. (Pubitemid 41587859)
24. Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology. 2000;39(12):1316-9. (Pubitemid 32045856)
25. Zen M, Bassi N, Nalotto L, Canova M, Bettio S, Gatto M, et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol. 2012;30(6):856-63.
26. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med. 1991;324(3):150-4.
27. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366-70. (Pubitemid 44032712)
28. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis. 1997;56(6):374-7. (Pubitemid 27305426)
29. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multiethnic cohort. Ann Rheum Dis. 2009;68(2):238-41.
30. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298(2):187-93. (Pubitemid 47057765)
31. Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005;14(2):106-12. (Pubitemid 40327660)
32. Ruiz-Irastorza G, Ugarte A, Egurbide MV, Garmendia M, Pijoan JI, Martinez-Berriotxoa A, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis. 2007;66(6):815-7.
33. Fessler BJ, Alarcon GS, McGwin G, Jr., Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473-80. (Pubitemid 40663939)
34. Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168-72. (Pubitemid 47309732)
35. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15(9):577-83. (Pubitemid 44661744)
36. Doria A, Gatto M, Zen M, Iaccarino L, Punzi L. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmunity reviews. 2014.